KY100001 / KPC Pharma - LARVOL DELTA

Safety,Tolerability, Pharmacokinetic,Pharmacodynamics and Efficacy of KY100001 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1; N=109; Not yet recruiting; Sponsor: Kunming Pharmaceuticals, Inc.

Clinical • New P1 trial • Cholangiocarcinoma • Gastrointestinal Cancer • Oncology • Solid Tumor • IDH1

Kunyao Group: Selective inhibitor of IDH1, a new drug under development, was approved for clinical trials [Google translation] (jrj.com) - "Kunyao Group (600422) issued an announcement stating that the company received the 'Drug Clinical Trial Approval Notice' issued by the National Medical Products Administration and agreed to the company to carry out treatment of isocitrate dehydrogenase in accordance with the submitted plan- 1 (IDH1) Clinical trials of solid tumors with gene mutations...The preclinical study of Kunyao Group showed that KY100001 has high target selectivity, demonstrated good tolerability in preclinical toxicology studies, and the safety risk is controllable."

Non-US regulatory • Oncology • Solid Tumor